Bilateral Parkinson's disease model rats exhibit hyperalgesia to subcutaneous formalin administration into the vibrissa pad

PLoS One. 2019 Dec 5;14(12):e0225928. doi: 10.1371/journal.pone.0225928. eCollection 2019.

Abstract

We bilaterally injected 6-hydroxydopamine (6-OHDA) into the medial forebrain bundle of rats and developed bilateral Parkinson's disease (PD) model rats in order to experimentally investigate the neural mechanisms underlying the alteration of nociception in the orofacial region of patients with PD. We explored the effects of dopamine depletion on nociception by investigating behavioral responses (face rubbing) triggered by subcutaneous administration of formalin into the vibrissa pad. We also assessed the number of c-Fos-immunoreactive (c-Fos-IR) cells in the superficial layers of the trigeminal spinal subnucleus caudalis (Vc). Subcutaneous formalin administration evoked a two-phase increase in face rubbing. We observed the first increase 0-5 min after formalin administration (first phase) and the second increase 10-60 min after administration (second phase). The number of face rubbing behaviors of 6OHDA-injected rats did not significantly change compared with saline-injected rats in both phases. Significant increase of c-Fos-IR cells in the Vc was found in 6-OHDA-injected rats after formalin administration compared with those in saline-injected rats after formalin administration. We also assessed expression of c-Fos-IR cells in the paraventricular nucleus (PVN), and significant decrease of c-Fos-IR cells in the PVN of 6-OHDA-injected rats was found. Taken together, these findings suggest that bilateral dopaminergic denervation evoked by 6-OHDA administration causes hyperalgesia in the trigeminal region and the PVN may be involved in the hyperalgesia.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Corpus Striatum / metabolism
  • Corpus Striatum / physiopathology
  • Disease Models, Animal*
  • Formaldehyde / administration & dosage
  • Formaldehyde / adverse effects
  • Hyperalgesia / etiology
  • Hyperalgesia / physiopathology*
  • Immunohistochemistry
  • Male
  • Parkinson Disease / complications
  • Parkinson Disease / etiology*
  • Parkinson Disease / metabolism
  • Parkinson Disease / physiopathology*
  • Rats
  • Substantia Nigra / metabolism
  • Substantia Nigra / physiopathology

Substances

  • Formaldehyde

Grants and funding

H.N received JSPS KAKENHI (Grant number: 23592988). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.